Current Status of β-Thalassemic Burden in India.
hemoglobin
preventive strategies
therapeutic strategies
β-Thalassemia
Journal
Hemoglobin
ISSN: 1532-432X
Titre abrégé: Hemoglobin
Pays: England
ID NLM: 7705865
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
medline:
11
12
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
ppublish
Résumé
Thalassemia is a major public health concern in India. The thalassemic burden in India is high, with an estimated 100,000 patients diagnosed with β-thalassemia syndrome. However, the exact number is unknown because of the absence of National Registries for patients. India alone contributes to approximately 25% of the global β-thalassemia burden. A possible option to control this burden is to endorse education and awareness programs, compulsory prenatal screening, and develop suitable facilities for genetic counseling, and availability of cost-effective diagnostic tests in India, especially in rural areas. In addition to the various clinical complications associated with thalassemia, lifelong intervention creates mental and physical trauma in patients and their relatives. Government and nongovernment organizations have initiated screening programs to prevent thalassemia. However, prenatal screening is not mandatory, and the reachability of screening programs in rural areas is yet to begin. This review article will discuss the progress in thalassemia research in India, including its prevalence, spectrum of β-thalassemia mutations, preventive and therapeutic measures, and awareness programs. More importantly, we will discuss the need and roadmap to strengthen prevention programs in India.
Identifiants
pubmed: 37947120
doi: 10.1080/03630269.2023.2269837
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM